Nu Skin (NUS): Buy, Sell, or Hold Post Q3 Earnings?

StockStory
2024-11-29
Nu Skin (NUS): Buy, Sell, or Hold Post Q3 Earnings?

Nu Skin’s stock price has taken a beating over the past six months, shedding 41.8% of its value and falling to $7.59 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

Is there a buying opportunity in Nu Skin, or does it present a risk to your portfolio? Check out our in-depth research report to see what our analysts have to say, it’s free.

Even with the cheaper entry price, we don't have much confidence in Nu Skin. Here are three reasons why we avoid NUS and a stock we'd rather own.

Why Do We Think Nu Skin Will Underperform?

With person-to-person marketing and sales rather than selling through retail stores, Nu Skin (NYSE:NUS) is a personal care and dietary supplements company that engages in direct selling.

1. Revenue Spiraling Downwards

A company’s long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Nu Skin struggled to consistently generate demand over the last three years as its sales dropped at a 13.8% annual rate. This was below our standards and signals it’s a low quality business.

2. Operating Margin Falling

Operating margin is an important measure of profitability accounting for key expenses such as marketing and advertising, IT systems, wages, and other administrative costs.

Analyzing the trend in its profitability, Nu Skin’s operating margin decreased by 7.6 percentage points over the last year. The company’s performance was poor no matter how you look at it. It shows operating expenses were rising and it couldn’t pass those costs onto its customers. Its operating margin for the trailing 12 months was negative 4.6%.

3. EPS Trending Down

Analyzing the change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions.

Sadly for Nu Skin, its EPS declined by more than its revenue over the last three years, dropping 42.7% annually. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand.

Final Judgment

Nu Skin doesn’t pass our quality test. After the recent drawdown, the stock trades at 8x forward price-to-earnings (or $7.59 per share). While this valuation is optically cheap, the potential downside is still huge given its shaky fundamentals. There are better stocks to buy right now. We’d suggest looking at Yum! Brands, an all-weather company that owns household favorite Taco Bell.

Stocks We Would Buy Instead of Nu Skin

With rates dropping, inflation stabilizing, and the elections in the rearview mirror, all signs point to the start of a new bull run - and we’re laser-focused on finding the best stocks for this upcoming cycle.

Put yourself in the driver’s seat by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.

Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,691% between September 2019 and September 2024) as well as under-the-radar businesses like Comfort Systems (+783% five-year return). Find your next big winner with StockStory today for free.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10